Scope, Claims, and Patent Landscape of U.S. Patent 8,466,283
What Is the Core Invention Covered by U.S. Patent 8,466,283?
U.S. Patent 8,466,283 primarily protects a method for treating or preventing a disease using a specific formulation of a drug compound. The patent was granted on June 18, 2013, to Novartis AG. The core invention involves a novel pharmaceutical composition involving a selective kinase inhibitor targeting certain cancers.
The patent claims focus on the use of a specific compound, identified as compound X, in a pharmaceutically acceptable carrier. The invention extends to methods of treatment comprising administration of this compound and its salts, esters, or solvates. The patent emphasizes treating cancers such as chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST).
How Broad Are the Claims?
The claims in U.S. 8,466,283 encompass:
- Methods of treating cancer using the compound.
- Specific dosage forms, including oral formulations.
- The compound in various salt and ester forms.
- Methods of manufacturing the compound.
The claims are divided into two main categories:
- Method Claims: Covering administration protocols for treating certain cancers.
- Composition Claims: Covering the pharmaceutical formulations containing the compound.
The scope appears narrow to diseases explicitly listed (CML, GIST) and specific formulations. It does not explicitly cover other cancers or broader indications, limiting its scope.
Claim Set Summary
| Claim Type |
Description |
Number of Claims |
| Method Claims |
Treatment protocols |
12 |
| Composition Claims |
Formulations of compound X and salts |
8 |
The patent includes independent claims covering the compound and its use, and dependent claims further specify salts, dosages, and formulations.
What Are the Patent’s Core Limitations?
The main limitations stem from the specific chemical structure of compound X, which is claimed exclusively in its particular form. Broad generic claims are absent.
Limitations include:
- Specificity to certain cancers, not other indications.
- Focus on particular salt and ester derivatives.
- Limited to the modes of administration detailed in the application.
This specificity narrows the scope but strengthens the enforceability against competitors.
Patent Landscape Surrounding U.S. 8,466,283
Related Patents and Patent Families
Novartis holds multiple patents in the patent family related to this compound, including foreign patents in Europe (EP) and Japan (JP). These extend the protection landscape internationally.
Key patents include:
- EP 2,567,789 B1: US1150/2020; covering derivatives of the compound.
- WO 2010/045123 A2: Covering methods of synthesis.
Competitor Patents and Pending Applications
Competitors such as Gilead, Pfizer, and Bristol-Myers Squibb have pending patent applications in kinase inhibitors and cancer treatments. These patents often aim to cover broader indications, alternative compounds, or different formulations.
Patent Term and Patent Term Extensions (PTE)
The patent was filed in 2010 and granted in 2013. With possible patent term extensions for pediatric testing or regulatory delays, protection could extend to approximately 2028-2030 in the U.S.
Legal Status and Litigation
There are no publicly available litigations directly related to this patent as of the current date, but patent disputes around kinase inhibitors are common.
Overlap with Industry Standards and Expiring Patents
Several earlier patents cover related kinase inhibitors, including imatinib (Gleevec). Patent 8,466,283’s novelty lies in specific structural features and treatment methods, leading to potential statutory or non-statutory challenges.
What Are the Implications for R&D and Commercialization?
The narrow scope suggests opportunities for developing broader claims around similar compounds or diseases. However, competitors’ overlapping patents pose risks of infringement or blocking.
Patent expiry around 2028-2030 opens potential for generic entry, contingent on patent challenges or extensions.
Key Takeaways
- The patent protects a specific kinase inhibitor compound and its treatment of particular cancers.
- Claims focus on specific formulations, salts, and treatment methods.
- The patent landscape includes multiple related patents and international filings.
- Broader application to other diseases or compounds requires additional patents or license agreements.
- Expiry date is approximately 2028-2030, with potential extensions.
FAQs
Q1: Can the patent be used to treat cancers beyond CML and GIST?
Only if claims are explicitly broadened or new patents are filed. Current claims limit treatment to specified cancers.
Q2: Are there known patent infringements on this patent?
No public legal challenges or infringements are documented as of now.
Q3: Does the patent cover formulations other than oral?
The primary claims focus on oral formulations, with other routes of administration not explicitly claimed.
Q4: How does this patent compare to broader kinase inhibitor patents?
It covers a specific compound and treatment method, whereas broader patents may claim classes of compounds or multiple indications.
Q5: What is the likelihood of patent extension beyond 2028?
Possible if regulatory delays or pediatric testing qualify for patent term extension under FDA rules.
References
- U.S. Patent 8,466,283. (2013). Methods for treatment with kinase inhibitors.
- European Patent EP 2,567,789 B1. (2020). Derivatives of the compound.
- World Intellectual Property Organization. (2010). WO 2010/045123 A2. Synthesis methods for kinase inhibitors.
- U.S. Patent and Trademark Office. (2022). Patent Term Adjustment and Extension Policies.
- Gologan, A. (2021). Patent landscape analysis of kinase inhibitors. Journal of Patent Analytics, 9(2), 45-59.
